• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

The Madras High Court ruling against Novartis on August 6 points out the long-term effects this decision will have on research and development for the pharma industry in India.

The lesson learnt from this case is that despite having introduced product patent protection for pharmaceuticals since 2005, the Indian Patent law has come under critical limelight, especially in lieu of proving the incremental efficacy of an already existing drug.

The pharmaceutical industry targets not just original innovations, but also accommodates incremental innovation without which further research might be stifled.

The case signals red to possible future innovation prospects for domestic pharma companies that may want to pursue research and development of an incremental nature.

Sukanya Natarajan New Delhi

More Stories on : Letters | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
For a pole position

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line